Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass (BRAC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Mias Pretorius, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00223704
First received: September 19, 2005
Last updated: October 15, 2013
Last verified: October 2013
  Purpose

Each year over a million patients worldwide undergo cardiac surgery requiring cardiopulmonary bypass (CPB). CPB is associated with significant morbidity including the transfusion of allogenic blood products, inflammation and hemodynamic instability. In fact, approximately 20% of all blood products transfused are associated with coronary artery bypass grafting procedures. Transfusion of allogenic blood products is associated with well-documented morbidity and increased mortality after cardiac surgery. Enhanced fibrinolysis contributes to increased blood product transfusion in the perioperative period. The current proposal tests the central hypothesis that endogenous bradykinin contributes to the hemodynamic, fibrinolytic and inflammatory response to CPB and that bradykinin receptor antagonism will reduce hypotension, inflammation and transfusion requirements. In SPECIFIC AIM 1 we will test the hypothesis that the fibrinolytic and inflammatory response to CPB differ during ACE inhibition and angiotensin II type 1 receptor antagonism. In SPECIFIC AIM 2 we will test the hypothesis that bradykinin B2 receptor antagonism attenuates the hemodynamic, fibrinolytic, and inflammatory response to CPB. In SPECIFIC AIM 3 we will test the hypothesis that bradykinin B2 receptor antagonism reduces the risk of allogenic blood product transfusion in patients undergoing CPB. These studies promise to provide important information regarding the effects of drugs that interrupt the RAS and generate new strategies to reduce morbidity in patients undergoing CPB.


Condition Intervention Phase
Cardiopulmonary Bypass
Inflammation
Fibrinolysis
Surgery
Drug: HOE 140
Drug: Aminocaproic Acid
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Allogenic Blood Product Transfusion Risk [ Time Frame: Patients were followed for the duration of hospital stay, an average of 6 days ] [ Designated as safety issue: No ]
    Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate.


Secondary Outcome Measures:
  • Units of Packed Red Blood Cells Transfused During Hospitalization [ Time Frame: Patients were followed for the duration of hospital stay, an average of 6 days ] [ Designated as safety issue: No ]
    Units of Packed Red Blood Cells Transfused

  • Units of Plasma Transfused During Hospitalization [ Time Frame: Patients were followed for the duration of hospital stay, an average of 6 days ] [ Designated as safety issue: No ]
    Units of plasma transfused

  • Inflammatory Response as Measured by Interleukin-6 [ Time Frame: Patients were followed from the start of surgery until postoperative day 2 ] [ Designated as safety issue: No ]
    Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2.

  • Fibrinolytic Response as Measured by D-dimer [ Time Frame: Patients were followed from the start of surgery until postoperative day 1 ] [ Designated as safety issue: No ]
    D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1


Enrollment: 150
Study Start Date: May 2006
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HOE 140
Bradykinin receptor antagonist
Drug: HOE 140
HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
Other Name: Icatibant
Active Comparator: Aminocaproic Acid
Antifibrinolytic
Drug: Aminocaproic Acid
Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
Other Names:
  • Amicar
  • EACA
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
Other Name: Placebo/Normal Saline

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects, 18 to 80 years of age, scheduled for elective CABG requiring CPB
  2. For female subjects, the following conditions must be met:

postmenopausal for at least 1 year, or status-post surgical sterilization, or if of childbearing potential, utilizing adequate birth control and willing to undergo urine beta-hcg testing prior to drug treatment and on every study day

Exclusion Criteria:

  1. Evidence of coagulopathy (INR greater than 1.7 without warfarin therapy)
  2. Preoperative hematocrit less than 30%
  3. Preoperative platelet count less than 100X109ml-1
  4. GPIIb/IIIa antagonist within 48 hours of surgery
  5. Emergency surgery
  6. Impaired renal function (serum creatinine >1.6 mg/dl)
  7. Pregnancy
  8. Breast-feeding
  9. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult
  10. History of alcohol or drug abuse
  11. Treatment with any investigational drug in the 1 month preceding the study
  12. Mental conditions rendering the subject unable to understand the nature, scope and possible consequences of the study
  13. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of completing the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00223704

Locations
United States, Tennessee
TN Valley Healthcare System
Nashville, Tennessee, United States, 37212
Vanderbilt University
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Mias Pretorius, MBChB Vanderbilt University
  More Information

Publications:
Responsible Party: Mias Pretorius, Associate Professor, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00223704     History of Changes
Other Study ID Numbers: IRB #051171, HL085740-02
Study First Received: September 19, 2005
Results First Received: July 29, 2013
Last Updated: October 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Vanderbilt University:
Coronary Artery Bypass
Blood Transfusion
Bradykinin Receptor Antagonism
Anti-Inflammatory Agents
Antifibrinolytic Agents

Additional relevant MeSH terms:
Inflammation
Pathologic Processes
Aminocaproic Acid
Antifibrinolytic Agents
Bradykinin
Kininogens
Cardiovascular Agents
Coagulants
Cysteine Proteinase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Hematologic Agents
Hemostatics
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on November 25, 2014